Personalized Neoantigen Peptide Vaccines: The Future of Cancer Immunotherapy
Personalized cancer vaccines using tumor-specific peptide neoantigens represent one of the most promising frontiers in oncology. With Phase 1 trials showing 5-year survival data and no recurrences in high-risk patients, this emerging technology is transforming our approach to treating cancer.